Taken together with our previous data, we posit that this significant difference in survival between low and high expressors is due in part to an elevated level of recruitment of immunosuppressive CCR2+/CX3CR1+ cells into the glioma microenvironment. The gene discussed is CCR2; the disease is central nervous system cancer.